Osteosarcoma News and Research

RSS
Between two and three percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with approximately 1,200 new cases diagnosed in the United States each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group (COG), the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.
PCI Biotech completes treatment of third dose group in phase I/II study of Amphinex in cancer patients

PCI Biotech completes treatment of third dose group in phase I/II study of Amphinex in cancer patients

Bone implants that support and release chemotherapeutical agents in ciclodextrin nanocapsule

Bone implants that support and release chemotherapeutical agents in ciclodextrin nanocapsule

Spectrum Pharmaceuticals to submit additional data for FUSILEV sNDA

Spectrum Pharmaceuticals to submit additional data for FUSILEV sNDA

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

Spectrum Pharmaceuticals receives Complete Response letter from the FDA for FUSILEV

Spectrum Pharmaceuticals receives Complete Response letter from the FDA for FUSILEV

Volvo Cars and ALSF support families affected by pediatric cancer

Volvo Cars and ALSF support families affected by pediatric cancer

A potentially better option to blocks tumors

A potentially better option to blocks tumors

Better health and prosperity in Europe via improved clinical research

Better health and prosperity in Europe via improved clinical research

Immune-based therapy approved in Europe for pediatric cancer patients

Immune-based therapy approved in Europe for pediatric cancer patients

UK survival for children's bone cancer lowest in Western Europe

UK survival for children's bone cancer lowest in Western Europe

Epeius Biotechnologies announces results of Rexin-G in chem-resistant metastatic soft tissue sarcoma and osteosarcoma

Epeius Biotechnologies announces results of Rexin-G in chem-resistant metastatic soft tissue sarcoma and osteosarcoma

Paving the way for future pan-European clinical trials

Paving the way for future pan-European clinical trials

Early stage drug shows promise against cancer cells from young patients

Early stage drug shows promise against cancer cells from young patients

IDM Pharma receives not approvable letter for Mifamurtide for treatment of osteosarcoma

IDM Pharma receives not approvable letter for Mifamurtide for treatment of osteosarcoma

Rapamycin study is first stage in development of new treatment

Rapamycin study is first stage in development of new treatment

CTRC enrolls first patients in study for sarcoma

CTRC enrolls first patients in study for sarcoma

IDM Pharma plans to amend NDA for Mifamurtide (L-MTP-PE) for the treatment of osteosarcoma

IDM Pharma plans to amend NDA for Mifamurtide (L-MTP-PE) for the treatment of osteosarcoma